Tags

Type your tag names separated by a space and hit enter

Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001.
Clin Ther. 2004 Apr; 26(4):522-30.CT

Abstract

BACKGROUND

Telithromycin is a new ketolide antimicrobial that was developed to provide good activity against resistant respiratory tract pathogens. PROTEKT US (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin in the United States) is a multicenter in vitro surveillance study that was initiated in 2000 to chart the emergence and spread of antimicrobial-resistant pathogens in patients with community-acquired respiratory tract infections (CARTIs).

OBJECTIVE

This article reports first-year results from PROTEKT US pertaining to the comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens.

METHODS

Data were compiled on the comparative in vitro activity of telithromycin and beta-lactams against Streptococcus pneumoniae (10,103 isolates), Streptococcus pyogenes (3918 isolates), and Haemophilus influenzae (2706 isolates). Minimum inhibitory concentrations (MICs) and susceptibilities were determined according to National Committee for Clinical Laboratory Standards methods.

RESULTS

In total, 38.8% (3920/10,103) of pneumococcal isolates were not susceptible to penicillin (12.5% [1266] intermediate [MIC, > or =0.12-1.0 mg/dL], 26.3% [2654] resistant [MIC, > or =2 mg/dL]). Telithromycin was highly active against S pneumoniae (MIC required to inhibit 90% of isolates [MIC(90)], 0.5 mg/L), with 99.6% (10,062/10,103) of isolates fully susceptible (MIC, < or =1 mg/L). Based on MIC(90)s, the rank order of antimicrobial activity was telithromycin (0.5 mg/L), followed by amoxicillin/clavulanate (2 mg/L), penicillin (4 mg/L), and cefuroxime (8 mg/L). Telithromycin retained high activity (MIC(90), 1 mg/L) against penicillin-resistant penumococci that showed high levels of coresistance to beta-lactams. All isolates of S pyogenes were fully susceptible to the beta-lactams tested. Beta-lactamase production was common among H influenzae isolates (28.3% [765/2706]). Telithromycin was active against H influenzae (MIC(90), 4 mg/L), irrespective of beta-lactamase production.

CONCLUSION

Overall, these findings from the first year of PROTEKT US support the potential value of telithromycin in the treatment of CARTIs.

Authors+Show Affiliations

Clinical Microbiology Laboratory, Vanderbilt University School of Medicine, Vanderbilt University Hospital, Nashville, TN 37201, USA. charles.stratton@vanderbilt.eduNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15189749

Citation

Stratton, Charles W., and Steven D. Brown. "Comparative in Vitro Activity of Telithromycin and Beta-lactam Antimicrobials Against Community-acquired Bacterial Respiratory Tract Pathogens in the United States: Findings From the PROTEKT US Study, 2000-2001." Clinical Therapeutics, vol. 26, no. 4, 2004, pp. 522-30.
Stratton CW, Brown SD. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001. Clin Ther. 2004;26(4):522-30.
Stratton, C. W., & Brown, S. D. (2004). Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001. Clinical Therapeutics, 26(4), 522-30.
Stratton CW, Brown SD. Comparative in Vitro Activity of Telithromycin and Beta-lactam Antimicrobials Against Community-acquired Bacterial Respiratory Tract Pathogens in the United States: Findings From the PROTEKT US Study, 2000-2001. Clin Ther. 2004;26(4):522-30. PubMed PMID: 15189749.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001. AU - Stratton,Charles W, AU - Brown,Steven D, PY - 2004/02/19/accepted PY - 2004/6/11/pubmed PY - 2004/6/30/medline PY - 2004/6/11/entrez SP - 522 EP - 30 JF - Clinical therapeutics JO - Clin Ther VL - 26 IS - 4 N2 - BACKGROUND: Telithromycin is a new ketolide antimicrobial that was developed to provide good activity against resistant respiratory tract pathogens. PROTEKT US (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin in the United States) is a multicenter in vitro surveillance study that was initiated in 2000 to chart the emergence and spread of antimicrobial-resistant pathogens in patients with community-acquired respiratory tract infections (CARTIs). OBJECTIVE: This article reports first-year results from PROTEKT US pertaining to the comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens. METHODS: Data were compiled on the comparative in vitro activity of telithromycin and beta-lactams against Streptococcus pneumoniae (10,103 isolates), Streptococcus pyogenes (3918 isolates), and Haemophilus influenzae (2706 isolates). Minimum inhibitory concentrations (MICs) and susceptibilities were determined according to National Committee for Clinical Laboratory Standards methods. RESULTS: In total, 38.8% (3920/10,103) of pneumococcal isolates were not susceptible to penicillin (12.5% [1266] intermediate [MIC, > or =0.12-1.0 mg/dL], 26.3% [2654] resistant [MIC, > or =2 mg/dL]). Telithromycin was highly active against S pneumoniae (MIC required to inhibit 90% of isolates [MIC(90)], 0.5 mg/L), with 99.6% (10,062/10,103) of isolates fully susceptible (MIC, < or =1 mg/L). Based on MIC(90)s, the rank order of antimicrobial activity was telithromycin (0.5 mg/L), followed by amoxicillin/clavulanate (2 mg/L), penicillin (4 mg/L), and cefuroxime (8 mg/L). Telithromycin retained high activity (MIC(90), 1 mg/L) against penicillin-resistant penumococci that showed high levels of coresistance to beta-lactams. All isolates of S pyogenes were fully susceptible to the beta-lactams tested. Beta-lactamase production was common among H influenzae isolates (28.3% [765/2706]). Telithromycin was active against H influenzae (MIC(90), 4 mg/L), irrespective of beta-lactamase production. CONCLUSION: Overall, these findings from the first year of PROTEKT US support the potential value of telithromycin in the treatment of CARTIs. SN - 0149-2918 UR - https://www.unboundmedicine.com/medline/citation/15189749/Comparative_in_vitro_activity_of_telithromycin_and_beta_lactam_antimicrobials_against_community_acquired_bacterial_respiratory_tract_pathogens_in_the_United_States:_findings_from_the_PROTEKT_US_study_2000_2001_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0149291804900549 DB - PRIME DP - Unbound Medicine ER -